Article Details
Retrieved on: 2021-06-24 14:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... including monoclonal antibodies such as aducanumab. The real costs to them of paying for these unproven medicines are huge. JAVIER GUZMAN
Article found on: www.economist.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here